Table 1.

Patient demographics

ProtocolTrial 1Trial 2Total
Total5485139
Sex
    M365692 (66%)
    F182947 (34%)
Age (y)
    Median (range)53 (21-67)49 (24-69)50 (21-69)
ECOG
    0435497 (70%)
    1-2113142 (30%)
HLA
    A*0201544094 (68%)
    Other04545 (32%)
Prior therapy
    None15520 (14%)
    HD IL-2133144 (32%)
    IFNα-2b*233962 (45%)
    Biochemotherapy101929 (21%)
    Chemotherapy62733 (24%)
    Other biological113142 (30%)
    Two or more184563 (45%)
Stage of disease
    M1a (only s.c., lymph node)81220 (14%)
    M1b (lung sole site of visceral met)111930 (22%)
    M1c (visceral met, or elevated lactate dehydrogenase)355489 (64%)
Treatment characteristics
    No. cycles
        Median (range)3.5 (1-12)4 (1-10)4 (1-12)
        1-2232548 (35%)
        3-4202545 (32%)
        5-652328 (20%)
        7-83710 (7%)
        >8358 (6%)
    Total dose (mg/kg), median (range)6 (3-24)28 (3-70)12 (3-70)
    Peptide administration
        Yes541973 (53%)
        No02121 (15%)
        Not eligible (non-A2)04545 (32%)
  • * Six of these 62 patients received IFNα-2b after resection of distant metastases.